Skip to content
Clinical Trials – home
Therapeutic area

Congenital, familial and genetic disorders – page 22

  • 803 clinical trials
  • 311 recruiting
  • 375 conditions
  • 27 countries

Conditions in this area

375 conditions with trials, the busiest first

Clinical trials in Congenital, familial and genetic disorders

803 trials across Europe, recruiting first

Type of trial
Recruitment status
Quick filters

803 clinical trials

Study on ATX-01 for Adults Aged 18-64 with Myotonic Dystrophy Type 1 (DM1)

Investigational
Countries:FranceFrance
  • Participants:18–64 years
  • Substances:16-Base Single Stranded Rna Targeting Mir-23B Linked To Oleic Acid
  • Sponsor:Arthex Biotech S.L.

Study on the Effects of Bisoprolol and Verapamil in Patients with Non-Obstructive Hypertrophic Cardiomyopathy

Registered drug
Countries:DenmarkDenmark
  • Participants:18–64 years · 65+ years
  • Substances:Bisoprolol Fumarate
  • Sponsor:Region Midtjylland

Study on the Effects of Dronabinol and Palmidrol for Adults with Tourette Syndrome

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Dronabinol
  • Sponsor:Neurothera Labs Inc.

Study on the Safety and Effects of Efpegerglucagon in Children Aged 2 and Older with Congenital Hyperinsulinism

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:0–17 years · 18–64 years
  • Substances:Efpegerglucagon
  • Sponsor:Hanmi Pharm. Co. Ltd.

Study of doxecitine and doxribtimine oral solution for adult patients with Thymidine Kinase 2 (TK2) Deficiency

InvestigationalNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Doxecitine
  • Sponsor:Hospital Universitario 12 De Octubre

Study on the Effects of Exagamglogene Autotemcel for Patients with Transfusion-Dependent Beta-Thalassemia or Severe Sickle Cell Disease

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:0–17 years · 18–64 years
  • Substances:Busulfan
  • Sponsor:Vertex Pharmaceuticals Inc.

EGFR gene mutation+1

Recruiting

Study on Patritumab Deruxtecan and Zirconium (89Zr) Patritumab Deruxtecan for Patients with Advanced EGFR Mutation Positive Lung Cancer

InvestigationalNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Patritumab Deruxtecan
  • Sponsor:Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Stichting

Study on the Safety and Effects of NXT007 for Patients with Severe or Moderate Hemophilia A

InvestigationalNo placebo
Countries:ItalyItaly
  • Participants:0–17 years · 18–64 years
  • Substances:RO7589655
  • Sponsor:F. Hoffmann-La Roche AG

Study on Long-Term Safety of mRNA-3705 for Patients with Methylmalonic Acidemia (MMA)

Registered drugNo placebo
Countries:FranceFrance
  • Participants:0–17 years · 18–64 years
  • Substances:Dexamethasone
  • Sponsor:Moderna Inc.

Study on the Effects of Sirolimus and Drug Combination for Children Under 4 Months with Tuberous Sclerosis Complex

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:0–17 years
  • Substances:Carbamazepine
  • Sponsor:Universitaetsklinikum Heidelberg AöR

Testosterone Treatment for Boys with Klinefelter Syndrome: A Study on Body Composition Changes During Puberty

Investigational
Countries:DenmarkDenmark
  • Participants:0–17 years
  • Substances:Testosterone
  • Sponsor:Rigshospitalet

Study on the Safety and Effects of Cipaglucosidase Alfa and Miglustat for Children with Infantile-onset Pompe Disease

InvestigationalNo placebo
Countries:DenmarkDenmark
  • Participants:0–17 years
  • Substances:Cipaglucosidase Alfa
  • Sponsor:Amicus Therapeutics Inc.

Substances studied in this area

The therapies tested most often in Congenital, familial and genetic disorders trials.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.